MLYS Chief Medical Officer Rodman David Malcom Buys $66K of Stock
Chief Medical Officer Rodman David Malcom picked up 4,584 shares of Mineralys Therapeutics, continuing a busy period of executive transactions.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rodman David Malcom, Chief Medical Officer at Mineralys Therapeutics, Inc. ($MLYS), bought 4,584 shares at an average price of $14.36, worth about $65,818.45, on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $MLYS is up 2.5% after 1 week, up 7.8% after 1 month and down 19.2% to date (from the $25.13 close on Jun 17, 2026).
MLYS
Mineralys Therapeutics, Inc.
Key Points
- Chief Medical Officer Rodman David Malcom purchased 4,584 shares of Mineralys Therapeutics, Inc. on June 17, 2026, valued at roughly $65,818.
- The stock traded around $25.13 recently, sitting below its 50-day moving average as the biotech firm works on cardiorenal therapies.
- Wall Street analysts maintain active coverage with firms like UBS and HC Wainwright & Co. tracking the clinical-stage biotech.
Get $MLYS trade alerts by text
We text you when insiders, Congress or big funds trade $MLYS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Mineralys Therapeutics, Inc. alert may contain errors. Disclosures
Executive Transaction at Mineralys Therapeutics
Mineralys Therapeutics, Inc. (NasdaqGS: MLYS) saw fresh insider activity when Chief Medical Officer Rodman David Malcom picked up 4,584 shares of the company. The transaction took place on June 17, 2026, executed at a price of $14.36 per share for a total value of $65,818.45. This filing captures part of a broader string of executive adjustments at the biotechnology firm during the middle of June.
Recent Insider Movements Across the Executive Team
This purchase adds to a busy month of Form 4 filings for the Radnor-based biotech company. On the exact same day of June 17, 2026, insider Daphne Karydas acquired 3,000 shares at $12.02 apiece, totaling $36,060, alongside planned sales from both Karydas and Malcom. Later in the month on June 26, 2026, Chief Commercial Officer Eric Warren was involved in transactions involving 104,124 shares. These varied insider trades reflect ongoing adjustments by leadership as the company advances its clinical pipeline.
Stock Valuation and Market Standing
Shares of Mineralys Therapeutics recently changed hands at $25.13. The company carries a market capitalization in the billions, though it does not feature a traditional P/E ratio since it remains pre-profit while funding its drug pipeline. The stock has experienced a 52-week trading range with a low of $22.30 and a high of $47.65.
Wall Street Analyst Views and Price Targets
Analyst sentiment remains active as firms evaluate the company's clinical prospects. On October 12, 2026, UBS initiated coverage on the stock with a Neutral rating and a $29.00 price target. On that same date, HC Wainwright & Co. reiterated its Buy rating on the company with a $56.00 price target. Across the broader analyst community, consensus targets sit higher than current trading levels.
Focusing on Aldosterone-Targeting Medicines
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines that target diseases driven by dysregulated aldosterone. Its lead candidate, lorundrostat, is an orally administered aldosterone synthase inhibitor being evaluated for cardiorenal conditions such as hypertension and chronic kidney disease. Executive trades come as the team continues research and development efforts across these key therapeutic areas.
What to Watch Next for the Biotech Firm
Investors tracking Mineralys Therapeutics can look toward the next scheduled financial results update on November 10, 2026, for further insight into the company's cash runway and clinical timeline. Additional regulatory filings will show whether executives continue modifying their share positions as the year winds down.
Related Filing Alerts
Source: Rodman David Malcom's Form 4 filing on $MLYS (Jun 17, 2026). Find the original filing: MLYS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts